



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee October 2022 Meeting Outcome**

	<b>Generic name</b>	<b>Brand name</b>	<b>Therapeutic Class</b>	<b>Meeting outcome</b>	<b>Primary reason for rejection<sup>1</sup></b>
1	Abemaciclib	Verzenio	Malignant disease and immunosuppression	Approved	
2	Acalabrutinib	Calquence	Malignant disease and immunosuppression	Pending	Pending further information
3	Adalimumab	Humira	Skin	Approved	
4	Avelumab	Bavencio	Malignant disease and immunosuppression	Pending	Pending further information
5	Baclofen intrathecal	Sintetica	Musculoskeletal and joint disease	Approved	
6	Botulinum Toxin A	Botox	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
7	Burosumab	Crysvita	Endocrine system	Pending	Pending further information
8	Canakinumab	Ilaris	Malignant disease and immunosuppression	Approved	
9	Ciprofloxacin / fluocinolone acetonide	Cetraxal Plus	Ear, nose, and oropharynx	Approved	
10	Dapagliflozin	Forxiga	Endocrine system	Approved	
11	Esketamine	Spravato	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
12	Gilteritinib	Xospata	Malignant disease and immunosuppression	Pending	Pending further information
13	Ibrutinib	Imbruvica	Malignant disease and immunosuppression	Approved	
14	Isatuximab	Sarclisa	Malignant disease and immunosuppression	Pending	Pending further information
15	Latanoprostene bunod	Vyzulta	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
16	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Approved	
17	Lorlatinib	Lorviqua	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
18	Luspatercept	Reblozyl	Nutrition and blood	Rejected	Insufficient evidence of long-term clinical outcome benefits

	<b>Generic name</b>	<b>Brand name</b>	<b>Therapeutic Class</b>	<b>Meeting outcome</b>	<b>Primary reason for rejection<sup>1</sup></b>
19	Midostaurin	Rydapt	Malignant disease and immunosuppression	Approved	
20	Nintedanib	Ofev	Respiratory system	Pending	Pending further information
21	Niraparib	Zejula	Malignant disease and immunosuppression	Approved	
22	Nivolumab / Ipilimumab	Opdivo / Yervoy	Malignant disease and immunosuppression	Pending	Pending further information
23	Olaparib	Lynparza	Malignant disease and immunosuppression	Approved	
24	Osimertinib	Tagrisso	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
25	Pegfilgrastim	Ziextenzo	Nutrition and blood	Approved	
26	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
27	Prasterone	Intrarosa	Obstetrics, gynaecology, and urinary-tract disorders	Rejected	Alternative(s) available in HADF with comparable benefits
28	Ranolazine	Ranexa	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
29	Ravulizumab	Ultomiris	Nutrition and blood	Pending	Pending further information
30	Ripretinib	Qinlock	Malignant disease and immunosuppression	Pending	Pending further information
31	Risdiplam	Evrysdi	Musculoskeletal and joint disease	Approved	
32	Tepotinib	Tepmetko	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
33	Trastuzumab deruxtecan	Enhertu	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
34	Upadacitinib	Rinvoq	Musculoskeletal and joint disease	Approved	

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.